Centessa Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Centessa Pharmaceuticals plc income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.006.850.000.000.00
Cost of Revenue0.000.000.000.000.00
Gross Profit0.006.850.000.000.00
Operating Expenses
Research & Development150.24124.41155.08316.119.30
Selling, General & Administrative50.8153.7355.2042.891.14
Operating Expenses201.06178.14210.28343.9210.44
Operating Income-201.06-171.28-210.28-374.08-10.44
Other Income/Expense
Interest Income14.0210.480.240.000.00
Interest Expense10.09-9.917.28-2.55-0.38
Other Income/Expense-31.865.430.364.370.16
Income
Income Before Tax-232.91-176.14-216.95-380.96-10.66
Income Tax Expense2.84-25.06-0.750.110.00
Net Income-235.76-151.09-216.21-381.07-10.66
Net Income - Continuous Operations-235.76-151.09-216.210.000.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-221.88-165.43-209.55-380.89-10.43
EBIT-222.82-166.24-209.68-380.96-10.44
Depreciation & Amortization0.940.300.130.030.01
Earnings Per Share
Basic EPS-2.00-2.00-2.00-5.00-1.00
Diluted EPS-2.00-2.00-2.00-5.00-1.00
Basic Shares Outstanding114.4796.1893.4075.1715.00
Diluted Shares Outstanding114.4796.1893.4075.1715.00